Can you regain weight after stopping peptides?

This question does not rely on anecdote; it has been tested directly, three times, in randomized designs:

• STEP 1 extension (semaglutide). Participants who lost an average of 17.3% of body weight over 68 weeks on semaglutide 2.4 mg then stopped treatment and were followed for another year. They regained an average of 11.6 percentage points — roughly two-thirds of what they had lost — leaving a net 5.6% loss from baseline at week 120. The authors concluded the findings "confirm the chronicity of obesity" (Wilding et al., Diabetes, Obesity and Metabolism 2022).
• STEP 4 (semaglutide). After a 20-week run-in on semaglutide, participants were randomized to continue or switch to placebo. Over the next 48 weeks, continuers lost a further 7.9%, while those switched to placebo regained 6.9% — a 14.8-percentage-point gap (Rubino et al., JAMA 2021).
• SURMOUNT-4 (tirzepatide). After 36 weeks of open-label tirzepatide, participants randomized to placebo regained 14.0% over the following year, versus a further 5.5% loss with continued treatment. Only 16.6% of those switched to placebo kept at least 80% of their initial weight loss, compared with 89.5% of those who stayed on the drug (Aronne et al., JAMA 2024).

The pattern is consistent across molecules and trial designs: regain begins after discontinuation and accumulates over months. Worth noting on the other side: regain in these studies was substantial but not always total — the STEP 1 extension cohort was still below baseline a year after stopping.

The regain is not a personal failure of the people in these trials — the same participants had just demonstrated, for over a year, that they could lose weight when the drug was on board. The drivers are mechanistic:

• The drug effect is ongoing, not curative. GLP-1–based drugs suppress appetite and slow gastric emptying only while present. These are peptides engineered to persist long enough for weekly dosing — not for months — so within weeks of the last dose, the signal is gone.
• Appetite regulation pushes back. Weight loss by any method triggers compensatory biology — increased hunger signaling and reduced energy expenditure — that persists after the loss and favors return toward the previous weight.
• The environment does not change. Food environment, stress, sleep, and habits that shaped weight before treatment are all still there after it.
• Cardiometabolic effects reverse too. The STEP 1 extension observed that improvements accompanying weight loss also trended back toward baseline after withdrawal — the regain question is about health markers, not just the scale.

This is why trial investigators describe obesity management in the same vocabulary used for blood pressure or cholesterol: a chronic condition where treatment effects last as long as treatment does.

Three implications follow directly from the data:

• "Stopping when I hit my goal" has a predictable trajectory. The withdrawal trials are effectively a preview of that plan, run under controlled conditions.
• Duration of treatment is a genuine open question. The trials establish what happens on-drug and off-drug; they do not establish how long treatment "should" last for any individual — that is an active area of research and a clinical decision.
• The regain data are specific to regulated GLP-1 medicines. For experimental research peptides marketed for weight loss, there are no withdrawal studies at all — the honest statement is that neither the loss nor the regain has been characterized.

None of this makes the drugs "not work"; the same trials show large, sustained effects while treatment continues. It means the effect is conditional on continued treatment — a property these medicines share with most chronic-disease pharmacology.

• How long do peptides take to work for weight loss?
• Can weight loss peptides affect muscle mass?
• Do peptides really work for weight loss?
• Catalog entries: semaglutide, tirzepatide, retatrutide.